Literature DB >> 8347124

An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes.

S Madden1, T F Woolf, W F Pool, B K Park.   

Abstract

Tacrine (1,2,3,4-tetrahydro-9-aminoacridine hydrochloride; THA) is known to undergo extensive oxidative metabolism to a variety of mono- and dihydroxylated metabolites in animals and humans. The potential for tacrine to undergo metabolism to stable, protein-reactive and cytotoxic metabolites has been investigated in incubations with human and rat liver microsomes. Using lymphocytes as sensitive markers to quantify cytotoxicity, THA (50 microM) underwent NADPH-dependent bioactivation to a cytotoxic metabolite(s). NADPH-dependent cytotoxicity in the presence of rat and human microsomes was 9.8 +/- 3.1% (P < 0.05 cf. -NADPH control) and 6.2 +/- 2.0% (P < 0.05 cf. -NADPH control), respectively. Stable and protein-reactive metabolites were also formed in microsomes from both species. These accounted for 28.2 +/- 12.7% and 1.22 +/- 0.79% of incubated radioactivity in human microsomes and 6.4 +/- 2.2% and 0.4 +/- 0.1% of incubated radioactivity in rat microsomes. In microsomes pooled from six human livers the NADPH-dependent cytotoxicity was 9.4 +/- 1.1%. Formation of stable and protein-reactive metabolites accounted for 29.2 +/- 2.3% and 1.2 +/- 1.0% of incubated radioactivity. Reduced glutathione (500 microM) completely blocked NADPH-dependent cytotoxicity and inhibited protein-reactive metabolite formation by 60% (P < 0.05). Ascorbic acid (500 microM) inhibited the generation of cytotoxic and protein-reactive metabolites by 75% (P < 0.05) and 35% (P < 0.05), respectively. Cyclohexene oxide was without effect. Human serum albumin was found to protect the lymphocytes against toxicity. In microsomes prepared from the livers of four donors known to have been smokers there were no significant differences in the generation of metabolites from THA compared with microsomes prepared from livers of non-smokers. Enoxacin, a specific inhibitor of cytochrome P450 1A2 significantly inhibited all routes of THA metabolism. We have therefore demonstrated that THA may be oxidatively metabolized to stable, protein-reactive and cytotoxic metabolites in human and rat liver microsomes. A number of inhibitors may affect these process, whilst inhibition by enoxacin indicates a role for cytochrome P450 1A2 in THA metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347124     DOI: 10.1016/0006-2952(93)90342-t

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Intracellular pH alterations induced by tacrine in a rat liver biliary epithelial cell line.

Authors:  D Lagadic-Gossmann; M Rissel; M Galisteo; A Guillouzo
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 4.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

5.  Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children.

Authors:  Esteban Mayayo-Sinués; Ana Fanlo; Blanca Sinués; Esteban Mayayo; Jose I Labarta; Angel García de Jalón; Angel Ferrández-Longás
Journal:  Eur J Clin Pharmacol       Date:  2006-01-12       Impact factor: 2.953

6.  Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.

Authors:  V J Green; M Pirmohamed; N R Kitteringham; M J Knapp; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

7.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

8.  Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.

Authors:  R J Fontana; T M deVries; T F Woolf; M J Knapp; A S Brown; L S Kaminsky; B K Tang; N L Foster; R R Brown; P B Watkins
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of tacrine.

Authors:  S Madden; V Spaldin; B K Park
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

10.  Tacrine sinusoidal uptake and biliary excretion in sandwich-cultured primary rat hepatocytes.

Authors:  Loqman A Mohamed; Amal Kaddoumi
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.